Cardiac tamponade and adrenal insufficiency due to pembrolizumab: a case report
- PMID: 31020118
- PMCID: PMC6177032
- DOI: 10.1093/ehjcr/yty038
Cardiac tamponade and adrenal insufficiency due to pembrolizumab: a case report
Abstract
Introduction: Patients who receive or have received anti-programmed cell-death-1 (PD-1) monoclonal antibodies can develop immune-related adverse events due to activation of the immune system.
Case presentation: We report a case of a patient who received pembrolizumab and presented with cardiac tamponade. Despite pericardial drainage, she persisted with refractory arterial hypotension due to secondary adrenal insufficiency. After initiating corticosteroid therapy, the patient recovered successfully.
Discussion: The association of pericarditis, hypophysitis and thyroid dysfunction support the diagnosis of a life-threatening immune-related adverse event due to pembrolizumab. In case of immune-related adverse events secondary to anti-PD-1 monoclonal antibodies, corticosteroid therapy should be promptly initiated in order to avoid major complications.
Keywords: Adrenal insufficiency; Cardiac tamponade; Case report; Corticosteroids; Pembrolizumab; Pericarditis.
Figures



References
-
- Imazio M, Gaita F.. Diagnosis and treatment of pericarditis. Heart 2015;101:1159–1168. - PubMed
-
- Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM.. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2768–2801. - PubMed
-
- Gentry J, Klein AL, Jellis CL.. Transient constrictive pericarditis: current diagnostic and therapeutic strategies. Curr Cardiol Rep 2016;18:41.. - PubMed
Publication types
LinkOut - more resources
Full Text Sources